PTPN11 and cancer: SHP2 is an exciting cancer drug target and four classes of inhibitors are known [for recent reviews, see (Vainonen et al., 2021; Kong & Long, 2022; Song et al., 2022)]: orthosteric inhibitors are directed to the catalytic pocket and block phosphatase activity of SHP2, allosteric inhibitors act as a molecular glue and lock SHP2 in the autoinhibited state, PROTAC degraders target SHP2 for E3 mediated degradation, and interaction inhibitors abolish protein-protein interactions of SHP2 with its binding partners.